Smith & Nephew/£SN

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Smith & Nephew

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Ticker

£SN
Sector

Primary listing

LSE

Employees

17,000

Smith & Nephew Metrics

BasicAdvanced
£12B
34.55
£0.41
0.62
£0.29
2.01%

What the Analysts think about Smith & Nephew

Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.

Bulls say / Bears say

First-half trading profit increased 11.2% to $523 million, lifting trading margin by 100 basis points to 17.7% and highlighting strong operational leverage and effective cost management (Reuters)
Shares jumped after announcing a $500 million share buyback in response to strong H1 results, showing robust cash flow and management confidence in future growth (Reuters)
Management reaffirmed full-year guidance for about 5% underlying revenue growth and a 19–20% trading profit margin despite headwinds, signaling strong confidence in hitting targets (Reuters)
Persistent challenges in China continued to offset growth in other regions, signaling weaker demand in a key emerging market (Reuters)
Foreign exchange volatility shaved 150 basis points off first-quarter underlying revenue growth, underscoring currency translation risk due to a strong dollar (Reuters)
Smith & Nephew expects a $15–20 million impact from US tariffs in 2025, leaving it exposed to policy-driven cost increases and possible margin erosion (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

Smith & Nephew Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Smith & Nephew Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £SN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Oct2
Smith & Nephew
DividendEx-dividend
Nov7
Smith & Nephew
DividendPayment
$0.15Per share
FAQs